Wells Fargo & Company MN Sells 20,692 Shares of DaVita Inc. (NYSE:DVA)

Wells Fargo & Company MN decreased its holdings in shares of DaVita Inc. (NYSE:DVA) by 38.1% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 33,607 shares of the company’s stock after selling 20,692 shares during the period. Wells Fargo & Company MN’s holdings in DaVita were worth $5,026,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Resona Asset Management Co. Ltd. acquired a new stake in shares of DaVita during the fourth quarter worth about $2,149,000. World Investment Advisors acquired a new stake in shares of DaVita in the fourth quarter worth $222,000. Huntington National Bank raised its holdings in shares of DaVita by 17.6% during the fourth quarter. Huntington National Bank now owns 903 shares of the company’s stock worth $135,000 after purchasing an additional 135 shares during the last quarter. Kesler Norman & Wride LLC lifted its position in DaVita by 40.2% during the fourth quarter. Kesler Norman & Wride LLC now owns 4,874 shares of the company’s stock valued at $729,000 after purchasing an additional 1,397 shares during the period. Finally, National Bank of Canada FI boosted its holdings in DaVita by 7.6% in the fourth quarter. National Bank of Canada FI now owns 41,125 shares of the company’s stock valued at $6,150,000 after purchasing an additional 2,893 shares during the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Stock Down 0.9 %

NYSE DVA opened at $140.21 on Monday. The business has a fifty day moving average price of $149.13 and a 200 day moving average price of $155.97. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The company has a market cap of $11.22 billion, a P/E ratio of 13.05, a P/E/G ratio of 1.07 and a beta of 1.04. DaVita Inc. has a one year low of $128.69 and a one year high of $179.60.

DaVita (NYSE:DVA) last issued its earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Research analysts anticipate that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on DVA shares. Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a research note on Friday, February 21st. Barclays upped their price objective on shares of DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 18th. StockNews.com upgraded DaVita from a “hold” rating to a “buy” rating in a research report on Thursday, April 10th. Finally, Cowen reissued a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $166.33.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.